No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SON240719P60000
- 1.67
- 0.000.00%
15min DelayClose Jul 16 15:59 ET
0.00High0.00Low
1.67Open1.67Pre Close0 Volume0 Open Interest60.00Strike Price0.00Turnover0.00%IV-13.73%PremiumJul 19, 2024Expiry Date8.71Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | Sonoco Products Co - Term Credit Agreement Provides Company With Ability to Borrow up to $700 Mln on an Unsecured Basis
Express News | Sonoco Products - Entered Into Credit Agreement With Lenders Party Thereto and JPMorgan Chase Bank, N.a., as Administrative Agent
BofA Securities Adjusts Price Target on Sonoco Products to $61 From $64
Sonoco Products (SON) has an average outperform rating and price target range of $53 to $65, according to analysts polled by Capital IQ.Price: 49.91, Change: +0.97, Percent Change: +1.98
Express News | Sonoco Products Co : BofA Global Research Cuts Price Objective to $61 From $64
Sonoco Products Is Maintained at Buy by Citigroup
Sonoco Products Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Sonoco Prods, Lowers Price Target to $60
Comments
Despite recent insider selling at Sonoco Products, shareholders need not worry deeply as insiders retain considerable company ownership, suggesting alignment with shareholders. Notably, the buying activity over the past year signals insider enthusiasm.
One Sonoco Products Insider Raised Stake By 99% In Previous YearSonoco's decent ROE comes with high debt levels, indicating risk. High ROEs without excessive debt denote good quality. Among companies with similar debt-to-equity ratios, a higher ROE is preferable.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Oak Street Health(OSH.US$ -up 26.6%
2. $Baidu(BIDU.US$ -up 7.5%
3. $BP PLC(BP.US$ -up 3.2%
4. $Fiserv(FISV.US$ -up 2.4%
5. $Mitsubishi UFJ Financial Group(MUFG.US$ -up 1.4%
6. $GlaxoSmithKline(GSK.US$ -up 0.8%
7. $Microsoft(MSFT.US$ -up 0.7%
8. $Sanofi(SNY.US$ -up 0.5%
9. $Activision Blizzard(ATVI.US$ -up 0.4% ...
Gap Ups
1. $Oak Street Health(OSH.US$ -up 26.6%
2. $Baidu(BIDU.US$ -up 7.5%
3. $BP PLC(BP.US$ -up 3.2%
4. $Fiserv(FISV.US$ -up 2.4%
5. $Mitsubishi UFJ Financial Group(MUFG.US$ -up 1.4%
6. $GlaxoSmithKline(GSK.US$ -up 0.8%
7. $Microsoft(MSFT.US$ -up 0.7%
8. $Sanofi(SNY.US$ -up 0.5%
9. $Activision Blizzard(ATVI.US$ -up 0.4% ...
+15
8
Gapping up
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
In reaction to earnings/guidance:
• $New Relic(NEWR.US$ +3.8% (guidance), $American Airlines(AAL.US$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
6
Upgrades
• $Coupang(CPNG.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
• $Coupang(CPNG.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
14
Read more